CUAMC
DSGN icon

China Universal Asset Management Company’s Design Therapeutics DSGN Stock Holding History

China Universal Asset Management Company’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
89,940
+54,831
+156% +$684K 0.08% 183
2026
Q1 		$374K Buy
35,109
+827
+2% +$8.37K 0.03% 290
2025
Q4 		$322K Sell
34,282
-700
-2% -$5.48K 0.02% 295
2025
Q3 		$263K Buy
34,982
+23,580
+207% +$118K 0.02% 308
2025
Q2 		$38.4K Buy
11,402
+45
+0.4% +$168 ﹤0.01% 433
2025
Q1 		$43.8K Sell
11,357
-649
-5% -$3.1K ﹤0.01% 426
2024
Q4 		$74.1K Buy
+12,006
New +$69.5K 0.01% 421
2023
Q4 		– Sell
-1,435
Closed -$3.39K – 440
2023
Q3 		$3.39K Buy
1,435
+702
+96% +$3.27K ﹤0.01% 409
2023
Q2 		$4.62K Sell
733
-25
-3% -$153 ﹤0.01% 379
2023
Q1 		$4.37K Buy
758
+190
+33% +$1.42K ﹤0.01% 383
2022
Q4 		$5.83K Buy
568
+45
+9% +$610 ﹤0.01% 280
2022
Q3 		$9K Buy
+523
New +$10.4K ﹤0.01% 214

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

China Universal Asset Management Company's DSGN Position: Q2 2026 in Review

China Universal Asset Management Company increased its Design Therapeutics (DSGN) stake by 156% in Q2 2026, buying an estimated $684K and bringing the position to 89,940 shares worth $1.3M. The position accounts for 0.08% of the portfolio, ranked #183.

China Universal Asset Management Company first reported a position in DSGN in Q3 2022 and has held it in 12 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • China Universal Asset Management Company held 89,940 shares of Design Therapeutics worth $1.3M as of Q2 2026.
  • China Universal Asset Management Company bought 54,831 Design Therapeutics shares in Q2 2026, an estimated $684K.
  • Design Therapeutics made up 0.08% of China Universal Asset Management Company's portfolio in Q2 2026, its #183 holding.
  • China Universal Asset Management Company first reported a position in Design Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.